about
High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague areaLocal treatment of hand-foot syndrome with uridine/thymidine: in vitro appraisal on a human keratinocyte cell line HaCaTRegorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study.Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study.Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges.Serum adiponectin relates to shortened overall survival in men with squamous cell esophageal cancer treated with preoperative concurrent chemoradiotherapy: a pilot studySelecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.Second consensus on medical treatment of metastatic breast cancer.Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialLessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations.Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.Third consensus on medical treatment of metastatic breast cancer.Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region.PET/CT significance for planning radiotherapy of head and neck cancer.Molecular characterization and heterogeneity of circulating tumor cells in breast cancer.MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.Cellular and humoral immunodeficiency in breast cancer patients resistant to hormone therapy.Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.Activity of fulvestrant in HER2-overexpressing advanced breast cancer.Adenocarcinoma of the lung among women: risk associated with smoking, prior lung disease, diet and menstrual and pregnancy history.Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.Highlights from the 7th central European lung cancer conference.Presentation, management and outcome of 32 patients with pregnancy-associated breast cancer: a matched controlled study.Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma.KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients.Analysis of human blood plasma and hen egg white by chiroptical spectroscopic methods (ECD, VCD, ROA).Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.Molecular pathological predictive diagnostics in a patient with non-small cell lung cancer treated with crizotinib therapy: A case report.[The Inclusion of a Gemcitabine + Nab-paclitaxel Regimen as a 2nd Line Treatment for Advanced Pancreatic Cancer - First Experience].Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy.Postoperative radiochemotherapy with weekly cisplatin in patients with head and neck cancer single-institution outcome analysis.The minimizing of fluorescence background in Raman optical activity and Raman spectra of human blood plasma.
P50
Q24813558-323DCBD1-BC95-4803-8DBF-95FD9F7CD62EQ28273580-CC03B534-C2EB-472F-B3DA-D8E4952A938BQ31131324-9F6822DE-9874-4FE2-BF15-80220C88F73CQ33327988-6EBE4D5F-4C8A-40A6-952A-A0E9BCCE0AC3Q33347231-A834E586-3E23-4AB4-AB25-BE3720BAE146Q33349587-4A122AEC-9893-4844-9B79-EDE42DD8ED45Q33373488-3C71B797-549A-4E68-9842-D29955D39D14Q33384947-680134CB-84D1-4987-9726-18A932B1DB72Q33828559-48F6863D-E9C3-4D67-8377-EEE59958C79DQ34584928-886CF31D-4938-4042-BFDD-A7C7A5F2B1ACQ34658278-44936636-C81D-41F5-9926-0B3962C6A5DAQ35211301-7B354114-9849-42E9-8282-262B37D76E7CQ35926639-462C90A2-FB0D-4927-8ACD-5B37FC867B53Q36532480-606FD75A-1861-422A-9FE5-A64793DD4BA2Q36611699-915ACC77-B7A4-496D-BDB1-CA3D7B242A19Q36649978-249AD016-0CA5-4E5C-9266-78C8EF7591B5Q36680024-EC885CEC-0AB9-4769-B210-A94AEB7359F6Q37360492-96FD275B-2DE0-48D2-A5AF-60317722AB86Q37532641-C19D6E04-BEDB-4252-9D8E-F2A7D00ADBD3Q37553629-47E504AA-A498-4212-AD3D-0CC741C6D902Q37971055-B947FCFA-88B8-4155-BE1D-5F758C19C1B7Q38016211-869DD8B5-3DDB-4D8E-900C-8E2062B500AAQ38621053-11C0F7E9-2234-4885-B9DE-222EA92D2DFDQ39161150-40AA0E0C-3EB7-4062-8D4A-B51193162F2FQ39320434-CDA64A7C-70C8-47AB-A531-47A88F49320BQ42882393-DAC08E86-D80D-4DC8-BD11-0793D1ADE0C9Q43252182-9B0477A6-0FFC-43F2-A70B-BFF936574C21Q44555871-0D9AA9C9-AAF9-465C-BF95-5B99688E0F8BQ45056439-734EF48F-1661-4D49-B092-5936002F4603Q45180324-20A7628D-0864-4A2E-B572-288A7367E364Q45884292-AB8DF749-B2EB-4237-8187-B154CE3C9BFBQ46549717-907DA2B6-8D5B-4D89-9B68-1FA8A196AB34Q46611019-14CDA29F-B23B-4137-8546-6C8339F37369Q46723406-3E746367-CF38-402E-8374-DD8102A07AC7Q47680099-83F9BDC8-AD3B-4B45-BB91-B951E0CEC7B6Q49375694-47BA14AF-099F-4EA0-A71E-5B86A5B5405AQ50133876-59CA8D41-B9DD-44ED-ABBD-83E12FD961A5Q50279529-4A8F8A48-6E5F-41E0-ABE1-C1E3495E2E64Q50975330-0EB093AA-B969-4151-B5BB-4D562FDA057CQ50997375-00923764-EA11-4BAB-99B1-DFF84BFD372B
P50
description
Czech oncologist
@en
Czech oncologist
@en-ca
Czech oncologist
@en-gb
oncólogo checo
@es
onderzoeker uit Tsjecho-Slowakije
@nl
český onkolog a radioterapeut
@cs
հետազոտող
@hy
طبيب أورام تشيكي
@ar
name
Lubos Petruzelka
@ast
Lubos Petruzelka
@es
Lubos Petruzelka
@nl
Lubos Petruzelka
@sl
Luboš Petruželka
@cs
Luboš Petruželka
@en
type
label
Lubos Petruzelka
@ast
Lubos Petruzelka
@es
Lubos Petruzelka
@nl
Lubos Petruzelka
@sl
Luboš Petruželka
@cs
Luboš Petruželka
@en
altLabel
Lubos Petruzelka
@en
Luboš Petruželka
@en
Petruzelka L.
@en
Petruzelka Lubos
@en
Petruzelka
@en
Petruželka L.
@en
Petruželka Luboš
@en
prefLabel
Lubos Petruzelka
@ast
Lubos Petruzelka
@es
Lubos Petruzelka
@nl
Lubos Petruzelka
@sl
Luboš Petruželka
@cs
Luboš Petruželka
@en
P214
P1053
A-2750-2017
P106
P1153
55942535800
P19
P21
P214
P31
P3829
P496
0000-0002-4397-0635
P569
1952-06-12T00:00:00Z
P691
jn19990209650